EyePoint shares are trading lower after the company announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU. The primary endpoint of change from baseline in best corrected visual acuity versus 2 mg aflibercept on-label control was not achieved in the full dataset.